• N&PD Moderators: Skorpio | thegreenhand

Ketamine salts solubility

Status
Not open for further replies.
1-(2,5-dimethoxy-3,4-di(methylthio)phenyl)-2-aminopropane.png


DIMMA
1-(2,5-dimethoxy-3,4-di(methylthio)phenyl)-2-aminopropane

1-(4-methoxy-3,5-di(methylthio)phenyl)-2-aminopropane.png


CYCLOBLACKOPS
1-(4-methoxy-3,5-di(methylthio)phenyl)-2-aminopropane

Please check Pubchem before claiming 'discovery' - these are already listed.
 

Often wondered if this would be active. After all, it has an ⭕ at the 2 & 5 position and a methylene at the 4 position. 2,5-dimethoxy 3,4-<something> compounds are active (but often less so than those with 3,4,5 pattern. But this keeps the whole of the aromatic planer which seems key to significant activity.

I would not like the task of making it. I suspect new techniques would have to be employed.
 

Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?​


Abstract​

Functional selectivity is the term that describes drugs that cause markedly different signaling through a single receptor (e.g., full agonist at one pathway and antagonist at a second). It has been widely recognized recently that this phenomenon impacts the understanding of mechanism of action of some drugs, and has relevance to drug discovery. One of the clinical areas where this mechanism has particular importance is in the treatment of schizophrenia. Antipsychotic drugs have been grouped according to both pattern of clinical action and mechanism of action. The original antipsychotic drugs such as chlorpromazine and haloperidol have been called typical or first generation. They cause both antipsychotic actions and many side effects (extrapyramidal and endocrine) that are ascribed to their high affinity dopamine D(2) receptor antagonism. Drugs such as clozapine, olanzapine, risperidone and others were then developed that avoided the neurological side effects (atypical or second generation antipsychotics). These compounds are divided mechanistically into those that are high affinity D(2) and 5-HT(2A) antagonists, and those that also bind with modest affinity to D(2), 5-HT(2A), and many other neuroreceptors. There is one approved third generation drug, aripiprazole, whose actions have been ascribed alternately to either D(2) partial agonism or D(2) functional selectivity. Although partial agonism has been the more widely accepted mechanism, the available data are inconsistent with this mechanism. Conversely, the D(2) functional selectivity hypothesis can accommodate all current data for aripiprazole, and also impacts on discovery compounds that are not pure D(2) antagonists.

good review about functional selectivity of newer antipsychotics.

 
Often wondered if this would be active. After all, it has an ⭕ at the 2 & 5 position and a methylene at the 4 position. 2,5-dimethoxy 3,4-<something> compounds are active (but often less so than those with 3,4,5 pattern. But this keeps the whole of the aromatic planer which seems key to significant activity.

i think i remember nichols mentioned that the furans or dihydrof. have to be in the exact position as in 2cb-fly otherwise no binding.
 
Fertile,

Did you mean for it to have an amine? If so, yes, I think it would be active. The way it's drawn, you've got an Ar-isobutyl group instead of an Ar-CH2CH(CH3)NH2.
 
think i remember nichols mentioned that the furans or dihydrof. have to be in the exact position as in 2cb-fly otherwise no binding.

Ah, I remember now. They tried making the difuranyl version of mescaline. This one didn’t work.
 
1-(3,4-dihydroxyphenyl)-1-hydroxyl-2-methylaminopropane.png


MONKEYPOX
1-(3,4-dihydroxyphenyl)-1-hydroxyl-2-methylaminopropane

I'm Just Doodling At This Point.
We've Thought Of Everything.
 
i think i remember nichols mentioned that the furans or dihydrof. have to be in the exact position as in 2cb-fly otherwise no binding.

I missed that - but fair enough. Don't ask, don't find out.
 
Fertile,

Did you mean for it to have an amine? If so, yes, I think it would be active. The way it's drawn, you've got an Ar-isobutyl group instead of an Ar-CH2CH(CH3)NH2.

NO- I mean the 2 compounds you drew are already listed in Pubchem. It's a free database which I have mentioned before. I'm not using some information source you have no access to, but I am BOTHERING to check. Also check Isomer Design for the Pihkals and Tihkals as the guy who runs it keeps a close eye on the various papers that Shulgin, the Nichols group and so on produce from time to time.

Also - hasn't the 2,4,5 pattern reached you yet. Shulgin established it but their hasn't been a single case (except the difurans) in which tetrasubstitution was of any benefit.

I would also like some kind of facile synthesis. If you can't make them, you don't get to name them. That is how medicinal chemistry works.
 
Ok,

Methamphetamine + Br2(l) -->
4-bromomethamphetamine or TRUMP.

Covered in Pubchem.... AGAIN. Look, I have clearly pointed to the database and it takes 30 seconds to check, but it's covered a LOT:

 
But I am interested in their human bioassayed effects, not who thought of it 1st.
 
But I am interested in their human bioassayed effects, not who thought of it 1st.
Then why bother giving them your own names if you're only interested in their bioassayed effects???
It does seem like your trying to claim ownership over some these molecules that are well established and created by other chemists.
I'm.more interested in hearing about your own unique and biologically active compounds.
 
I would think at least one of my structures has never been thought of, but I've never used PubChem and am pretty much through with this entire thread.

I am creatively exhausted.
And don't feel like arguing.

This thread is what it is.
 
Last edited:
For example, someone will aways say, "Halogenated amphetamines are neurotoxic."

And I actually tested many of them on myself!

Or, "MDMA makes you gay."
Or, "There is strychnine in LSD."

I don't care to argue, sorry.
 
Status
Not open for further replies.
Top